Policy & Regulation
Oncopeptides four abstracts highlighting Melflufen clinical programmes accepted for presentation at 24th EHA Congress in June 2019
17 May 2019 -

Oncopeptides AB (STO: ONCO), a pharmaceutical company developing drugs for the treatment of cancer, announced on Thursday the acceptance of a total of four abstracts for presentation at the 24th Congress of European Haematology Association (EHA) meeting (from 13 June 2018 to 16 June 2018) at Amsterdam, Netherlands.

Reportedly, updated data from the phase 2 HORIZON study evaluating melflufen for the treatment of relapsed/refractory multiple myeloma (RRMM) patients with no or limited remaining treatment options will be presented as an oral presentation by Professor Paul G Richardson in the session 'Novel strategies in multiple myeloma' on 16 June 2019 at 08.45 hours, CET, in the auditorium.

Also, three poster presentations, one of which is from the ongoing phase 1/2 ANCHOR study, will also be presented.

According to the company, the data in the abstracts regarding the ANCHOR and HORIZON studies is from 6 February 2019 and consequently similar to the data already presented at ASH 2018. Additional data supporting melflufen's activity have been generated during the spring of 2019 and will be presented in full at EHA.